FINAL ORAL PROGRAMME
& POSTER PROGRAMME
MVADS 2015

ADVISORY SCIENTIFIC PANEL

Local Organisers: Edmund J. Remarque (BPRC, Rijswijk, The Netherlands) and Ferry Ossendorp (Leiden University Medical Center, Leiden, The Netherlands)

Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Erik Lindblad (Brenntag Biosector, Copenhagen, Denmark)
Stein Lokstad (Brenntag Biosector, Copenhagen, Denmark)
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)
Heather Davis (Pfizer Vaccine Research, Ottawa, Canada)
Derek O’Hagan (Novartis Vaccines, Cambridge, Massachusetts, USA)
Adriana Baz Morelli (CSL Ltd, Melbourne, Australia)
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)
John Clements (Tulane University, New Orleans, Louisiana, USA)
Gwyn Davies (St. George’s, University of London, UK)
Nathalie Garcon (BIOASTER Technology Research Institute, Lyon, France)
Niranjan Sardesai (Inovio Pharmaceuticals, Blue Bell, Pennsylvania, USA)

Greg Glenn (Novavax Inc., Maryland, USA)
Virgil Schijns (Wageningen University, The Netherlands)
Gary Ott (Dynavax Inc., San Diego, California, USA)
Burkhard Becher (University of Zurich, Zurich, Switzerland)
Stephane Ascarateil (SEPPIC, Paris, France)
Geert Vanden Bossche (UNIVAC LLC, Belgium)
Steve Reed (IDRI, Seattle, USA)
Martin Bachmann (University of Zurich, Switzerland & University of Oxford, UK)
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)
Nicolas Havelange (EVI, Heidelberg, Germany)
Jeffrey A. Hubbell (EPFL, Lausanne, Switzerland)
Behazine Combadiere (Cimi-Paris, Paris, France)
07.45 onwards
Registration
08.55-09.00
‘Welcome to LUMC Leiden’
Ferry Ossendorp (University of Leiden, Leiden, The Netherlands)

SESSION 1: PLENARY SESSION

Moderator: Ferry Ossendorp (University of Leiden, Leiden, The Netherlands)

KEYNOTE:
09.00-09.30
‘Antitumour vaccines’
Kees Melief (Leiden University Medical Centre, Leiden, The Netherlands)
09.30-10.00
‘Designing the next generation of vaccine adjuvants’
Derek O’Hagan (Novartis Vaccines, Cambridge, Massachusetts, USA)

10.00-10.30
‘Adjuvants for unmet needs’
Steve Reed (IDRI, Seattle, Washington, USA)

10.30-11.00
‘Janssen ebola vaccine development update’
Benoit Callendret (Janssen Vaccines, Leiden, The Netherlands)

11.00-11.20
Coffee Break & Poster Set-Up

SESSION 2: VACCINES

Moderator: Edmond J. Remarque (BPRC, Rijswijk, The Netherlands)

11.20-11.40
‘Hapten- and peptide-conjugate vaccines: The importance of conjugate design and adjuvants’
Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)

11.40-12.00
‘Clinical development of an oral vaccine to prevent Ebola virus infection’
Sean N. Tucker (Vaxart Inc., South San Francisco, California, USA)

12.00-12.20
‘DNA vaccination and immunoprophylaxis for Ebola virus’
Niranjan Y. Sardesai (INOVIO Inc., Plymouth Meeting, Pennsylvania, USA)

12.20-12.40
‘Developing novel malaria vaccine delivery platforms for induction of very high antibody responses: Towards clinical development’
Sumi Biswas (University of Oxford, Oxford, UK)

12.40-12.50
‘Optimization of the process for making clinical supplies of an enveloped virus-like particle vaccine for cytomegalovirus’
Marc Kirchmeier (VBI Vaccines, Cambridge, Massachusetts, USA)

13.00-14.00
Lunch Break, Posters & Exhibits

SESSION 3: SPECIAL SESSION – BIOMARKERS OF VACCINE/ADJUVANT POTENCY AND SAFETY (BVAPS)

Moderator: Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

14.00-14.10
‘Introduction to BVAPS special session’
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

14.10-14.30
‘Smart data in vaccine research’
Nathalie Garcon (BioAster, Lyon, France)

14.30-14.50
‘The ink spots and signatures of adjuvants’
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

14.50-15.10
‘Transcriptional profile reveals mechanism of action of ISCOMATRIX adjuvant’
Anne Walter (CSL Ltd, Melbourne, Victoria, Australia)

15.10-15.30
‘Molecular biomarkers of human skin vaccination’
Behazine Combadiere (Centre d’Immunologie et des Maladies Infectieuses Cimi, Paris, France)

15.50-16.10
‘Biomarkers in tuberculosis’
Tom M.H. Ottenhof (Leiden University Medical School, Leiden, The Netherlands)

16.10-16.30
‘Integrated testing strategies for adjuvant development’
J.J. Bajramovic, J.J.J. Veth, E.A. Zuiderveld-Sick and L. van Straalen (Biomedical Primate Research Centre, Rijswijk, The Netherlands)

16.30-16.45
Tea Break, Posters & Exhibits

SESSION 4: VACCINES/ADJUVANTS DELIVERY

Moderator: Nathalie Garcon (BioAster, Lyon, France)

16.45-17.05
‘Adjuvant data base project: Can we predict vaccine MOA and/or side effect?’
Ken Ishi (NIBIO/University of Osaka, Osaka, Japan)

17.05-17.20
‘Induction of protective immune response in mice by intramuscular, intranasal and combined IM and IN delivery of norovirus VLP candidate vaccine’
Maria Malm, Kirsi Tamminen, Timo Vesikari and Vesna Blazevic (University of Tampere, Tampere, Finland)

17.20-17.35
‘PPD: A gold standard adjuvant that was never adopted clinically but should be revisited’
Peter Lachmann (University of Cambridge, Cambridge, UK)

17.35-17.50
‘Insights into the delivery of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: Formulation optimization, biodistribution and immunogenicity in comparison to a licensed protein vaccine’
Anne Endmann, Detlef Oswald, Oliver Riede, Eduard G. Talman, Roelien E. Vos, Matthias Schroff, Christiane Kleuss, Marcel H.J. Ruiters and Christiane Juhrs (MOLOGEN AG, Berlin, Germany)

17.50-18.05
‘Adjuvanted peptide-loaded virosomes as an influenza T-cell vaccine’
Peter Soema, Sietske Rosendahl Huber, Geert-Jan Willems, Wim Jiskoot, Gideon Kersten and Jean-Pierre Amorij (Intravacc, Bilthoven, The Netherlands)

18.05-18.20
‘DNA vaccine delivery platform and adjuvant systems’
Luigi Aurisicchio (Takis Biotech, Rome, Italy)

Poster Session
### SESSION 5: SPECIAL SESSION – VACCINE FORMULATIONS FOR HIV VACCINES

**Moderator:** Dennis Christensen (SSI, Copenhagen, Denmark)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45-09.00</td>
<td>'Overview of the HIV vaccine adjuvant pipeline: NIH perspective' Cesar Boggiano (NIH, Bethesda, Maryland, USA)</td>
</tr>
<tr>
<td>09.00-09.15</td>
<td>'Overview of the HIV vaccine adjuvant pipeline: Gates Foundation perspective' Magda Moutafis (Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA)</td>
</tr>
<tr>
<td>09.15-09.45</td>
<td>'Overview on clinical evaluation of HIV-Env-based adjuvanted vaccines' Julie McElrath (Fred Hutchinson Cancer Research Center, Seattle, Washington, USA)</td>
</tr>
<tr>
<td>09.45-10.15</td>
<td>'The non-human primate model for mechanistic studies of HIV-Env-based adjuvanted vaccines' Karin Lore (Karolinska Institutet, Solna, Sweden)</td>
</tr>
<tr>
<td>10.15-10.30</td>
<td>'How can IL-4R antagonist adjuvanted HIV mucosal/systemic prime-boost vaccination strategy induce high avidity HIV-specific T and B cell immunity' Charani Ranasinghe, Megat Abd Hamid, Matthew Worley, Alice Ng, Ronald Jackson and Robert Center (The Australian National University, Acton, ACT, Australia)</td>
</tr>
<tr>
<td>10.30-10.45</td>
<td>'Development of consensus gene vaccines for drug-resistant HIV' Maria Issagouliants (Karolinska Institutet, Stockholm, Sweden/Riga Stradins University, Riga, Latvia)</td>
</tr>
<tr>
<td>11.00-11.10</td>
<td>Coffee Break, Posters &amp; Exhibits</td>
</tr>
</tbody>
</table>

### SESSION 6: MUCOSAL/INTRANASAL

**Moderator:** Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.10-11.35</td>
<td>'Vaccines and adjuvants for mucosal immunity' Ali Harandi (University of Gothenburg, Gothenburg, Sweden)</td>
</tr>
<tr>
<td>11.35-12.00</td>
<td>'Induction of mucosal memory with adjuvants' Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)</td>
</tr>
<tr>
<td>12.00-12.20</td>
<td>'Development of an inactivated nasal influenza vaccine' Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)</td>
</tr>
<tr>
<td>12.20-12.40</td>
<td>'Development of the intranasal RSV vaccine SyntGEM' Kees Leenhouts (Mucosis B.V., Groningen, The Netherlands)</td>
</tr>
<tr>
<td>12.40-13.00</td>
<td>'RSV virosome vaccine' Toon Stegmann (Mymetics BV, Leiden, The Netherlands)</td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch Break, Posters &amp; Exhibits</td>
</tr>
</tbody>
</table>

### SESSION 7: MECHANISMS, FORMULATION & DESIGN

**Moderator:** Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-14.20</td>
<td>'The epitope dilution phenomenon: Lessons learnt from a polymorphic malaria vaccine candidate (AMA1) and applicability to polymorphic vaccine antigens' Edmond J. Rermarque (Biomedical Primate Research Centre, Rijswijk, The Netherlands)</td>
</tr>
<tr>
<td>14.20-14.40</td>
<td>'Rational design of TLR4 agonist based combination adjuvants' Darrick Carter (IDRI, Seattle, Washington, USA)</td>
</tr>
<tr>
<td>14.40-15.00</td>
<td>'Better aluminum adjuvant vaccine formulations through innovative analytical methods, high-throughput analytics, and design of experiment (DoE)' Patrick Ahl, Henrik-Mach, David Thiriot, Ramesh Chintala, Erin Green-Trexler, Bei Wang, Chris Mensch, Binghua Hu, Heidi Ploix, Sheng-ching Wang, Cheryl Piatto, Deborah Gross, Philip Villari, Thomas Griffiths, Philip Troilo, Jayanthi Wolf and Jeffrey Blue (Merck Research Laboratories, West Point, Pennsylvania, USA)</td>
</tr>
</tbody>
</table>

---

**SESSION 8: ADJUVANTS**

**Moderator:** Steve Reed (IDRI, Seattle, Washington, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.20-16.40</td>
<td>'Development and adjuvant activity of Alum-based TLR ligand formulation' Mark Orr (IDRI, Seattle, Washington, USA)</td>
</tr>
<tr>
<td>16.40-17.00</td>
<td>'Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor' Ioanna Skountzou, Joanna A. Pulk-Penalzo, Bishu Sapkota, E. Stein Esser, Richard W. Comans and Brian P. Pollack (Emory University, Atlanta, Georgia, USA)</td>
</tr>
<tr>
<td>17.00-17.20</td>
<td>'Comparative evaluation of the Cationic Adjuvant Formulation CAF09 versus CAF01 in non-human primates' Frank A.W. Verreck, Sommandas, Sumera Y. Younis, Claudia C. Sombroek, Richard A.W. Vervenne, Saskia Burm, Jennifer Veth, Jeffrey Barjamovic, K.S. Korsholm, Clemens Kocken, Peter L. Andersen and Dennis Christensen (Biomedical Primate Research Centre, Rijswijk, The Netherlands / Statens Serum Institute, Copenhagen, Denmark)</td>
</tr>
<tr>
<td>17.20-17.40</td>
<td>'Adjuvant combinations comprising the synthetic TLR4 agonist E6020: Optimization of formulation parameters' Jean Haensler (Sanofi Pasteur, Marcy l’Etoile, France)</td>
</tr>
<tr>
<td>17.40-18.00</td>
<td>'NanoQuil™ – a new generation of safe and effective nanoparticulate saponin based adjuvants' Kefei Hu (Brenntag Biosector A/S, Frederikssund, Denmark)</td>
</tr>
<tr>
<td>18.00-18.20</td>
<td>'Montanide vaccine adjuvants, mechanisms of action and delivery systems for vaccines formulations' Aude Puget (SEPPIC, Paris, France)</td>
</tr>
<tr>
<td>18.20-18.40</td>
<td>'New adjuvants for developing countries' Isaisas Raw, W. Quintilio, C. Myiaki, A. Precioso and P.L. Ho (Butantan Institute, Sao Paulo, Brazil)</td>
</tr>
</tbody>
</table>
SESSION 9: SAFETY, EFFICACY & TESTING
Moderator: Anne Walter (CSL Ltd, Melbourne, Victoria, Australia)

08.40-09.00
‘Accelerated vaccine design and efficacy testing using the IVAX toolkit’
Annie S. De Groot, Frances Terry, Leonard Moise, Andres Gutierrez, Rui Liu, Ryan Tassone, Rebecca Martin and William Martin
(EnvX Inc./University of Rhode Island, Providence, Rhode Island, USA)

09.00-09.20
‘Electroporation strategies to enhance DNA vaccine delivery into the skin’
Trevor Smith (Inovio Pharmaceuticals, San Diego, California, USA)

09.20-09.40
‘Safety and tolerability evaluation of the use of Montanide™ ISA™ 51 as vaccine adjuvant: A systematic review’
Eva van Doorn, Heng Liu, Anke Huckriede and Eelko Hak
(University of Groningen, Groningen, The Netherlands)

09.40-10.00
‘A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile’
Johannes Lutz (CureVac GmbH, Tubingen, Germany)

10.00-10.20
‘Efficacy of ACI-35, a liposomal anti-p[ospho Tau vaccine in an Adeno-associated virus (AAV) Tau P301S mouse model of Alzheimer’s disease’
M. Vukicevic, M. Pilhgren, V. Gafner, K. Piorkowska, N. Chuaard, V. Giriens, P. Valdes, S. Nazeeruddin, P. Collin, A. Pfeiffer, B. Schneider and A. Muhs
(AC Immune SA, Lausanne, Switzerland)

10.20-10.40
‘A novel nano-membrane technology platform for vaccine development’
Robin Löving, Martina Soldem, Henrik Garoff, Gunilla Karlsson Hedestam and Jens Frauenfeld
(Karolinska Institutet, Stockholm, Sweden)

10.40-11.00
Coffee Break, Posters & Exhibits

SESSION 10: SKIN DELIVERY & ALTERNATES
Moderator: Derek O’Hagan (Novartis Vaccines, Cambridge, Massachusetts, USA)

11.00-11.25
‘Microneedles for dermal delivery of vaccines’
Joke Bowstra (Leiden/Amsterdam Center for Drug Research, The Netherlands)

11.25-11.45
‘The use of TLR 7/8 agonists as vaccine adjuvants and microneedle delivery systems to enhance vaccine responses’
Mark Tomai (3M Drug Delivery Systems, St. Paul, Minnesota, USA)

11.45-12.05
‘Laser-assisted intradermal delivery of Xc11-specific fusion vaccines induces potent anti-tumor response’
Dorothea Terhorst, Elmira Lechat, Even Fossum, Bjarne Bogen, Sandrine Henri and Bernard Malissen
(Charite-Universitatsmedizin, Berlin, Germany / University of Oslo / CNRS Marseille-Luminy / Pan-Tec Biosolutions AG, Liechtenstein)

12.05-12.20
‘Alternative delivery of a thermostable inactivated polio vaccine’
Heleen Kraan, Ivo Ploemen, Gijsbert van de Wijdeven, Gideon Kersten and Jean-Pierre Amorji
(Intravacc, Bilthoven, The Netherlands)

12.20-12.40
‘Delivery of flu vaccines using microneedles’
Mamsohnan Singh (Novartis Vaccines, Holly Springs, North Carolina, USA)

12.40-13.00
‘Immunogenicity of adjuvanted vaccines in ImmunPatch dissolvable microneedle patches’
Anne Moore, Olivia Flynn and Kate Dillane (University College Cork, Cork, Ireland)

13.00-14.00
Lunch Break, Posters, Exhibits

SESSION 11: SYNTHETIC CANCER VACCINES
Moderator: Ferry Ossendorp
(Leiden University Medical Centre, Leiden, The Netherlands)

14.00-14.20
‘Liposome formulated peptide cancer vaccines’
Eleni Varipataki (LACDR, Leiden University, Leiden, The Netherlands)

14.20-14.40
‘Synthetic adjuvants’
Dimtri Filippov (University Leiden, Leiden, The Netherlands)

14.40-15.00
‘TLR and NLR targeted cancer vaccines’
Gijs Zom (Leiden University Medical Centre, Leiden, The Netherlands)

15.00-15.20
‘Conjugated peptide cancer vaccines: Towards a clinical study’
Ferry Ossendorp (Leiden University Medical Centre, Leiden, The Netherlands)

15.20-15.35
Tea Break, Posters Breakdown & Exhibits Breakdown

SESSION 12: CLOSING SESSION – LATEBREAKER PRESENTATIONS
Moderator: Edmond J. Remarque (BPRC, Rijswijk, The Netherlands)

15.35-15.50
‘Matrix-M adjuvant’
Karim Lowgren (Novavax AB, Stockholm, Sweden)

16.05-16.20
‘Matrix-M adjuvant enhancement of the humoral and cellular immune response to a Zaire Ebola virus glycoprotein nanoparticle vaccine’
Halfeng Song (Novavax, Gaithersburg, Maryland, USA)

16.30-16.45
‘Immunogenicity and efficacy of a Zaire Ebola glycoprotein nanoparticle vaccine in nonhuman primates’
David Flyer (Novavax, Gaithersburg, Maryland, USA)

16.45-17.00
‘Utilising the unique antigen targeting properties of ISCOMATRIX adjuvant for therapeutic vaccination against Epstein Barr Virus’
Neil Robson (University of Glasgow, Glasgow, UK)

17.00-17.15
‘In vivo imaging of gene reporter expressing in tracing gene delivery and specific immune responses in gene immunization’
Stefan Petkov (Karolinska Institutet, Stockholm, Sweden)

17.15-17.30
‘Objective, qualitative and quantitative assessment of viruses and nanoparticles’
Musa Sani (Vironova AB, Stockholm, Sweden)
Poster 101  ‘Adenoviral dodecahedron, a proteinaceous, multivalent delivery and vaccination nanoplatform with adjuvant properties’
Ewa Szolajska et al. (Polish Academy of Sciences, Warsaw, Poland)

Poster 102  ‘Layer-by-layer assembly of inactivated poliovirus and N-trimethyl chitosan on pH-sensitive microneedles for dermal vaccination’
Koen van der Maaden et al. (Leiden Academic Centre for Drug Research, Leiden, The Netherlands)

Poster 103  ‘Cell-penetrating peptide mediated DNA delivery via dissolving microneedles: An innovative platform for DNA vaccination’
J. McCaffrey et al. (Queen’s University Belfast, Belfast, Northern Ireland, UK)

Poster 104  ‘Vaccine delivery technology at Intravacc’
Ivo Ploemen et al. (Intravacc, Bilthoven, The Netherlands)

Poster 105  ‘Development of a novel, dissolvable microneedle system encapsulating peptide/DNA nanoparticles for prostate cancer vaccination’
Grace Cole et al. (Queens University Belfast, Belfast, Antrim, Northern Ireland, UK)

Poster 106  ‘The Th17 response is differentially enhanced by c-di-AMP and cGAMP’
Ivana Skrniugj et al. (Heinrich Heine University of Duesseldorf, Germany)

Poster 107  ‘Norovirus-VLPs used for delivery of pre-erythrocytic targets induce functional immunity against sporozoite infection’
Evelina Angov et al. (Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

Poster 108  ‘Preclinical comparison of a particulate and soluble CSP based vaccine against malaria’
Sheetij Dutta et al. (Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

Poster 109  ‘Versatile i-particles from Adjuvatis, for safer and efficient, fully metabolizable vaccines’
Charlotte Primard et al. (ADJUVATIS, Lyon, France)

Poster 110  ‘Neutralizing antibody responses induced by intranasal vaccination with an inactivated whole virion of influenza A(H5N1) virus in healthy human adults’
Akira Aina et al. (National Institute of Infectious Diseases, Tokyo, Japan)

Poster 111  ‘Hepatitis B virus core particles as a platform for vaccine development’
Arnis Strods et al. (Latvian Biomedical Research and Study Centre, Riga, Latvia)

Poster 112  ‘Safety and efficacy of a live Salmonella Gallinarum vaccine candidate JOL1355 compared with a commercial vaccine SG9R in chickens’
John Hwa Lee (Chonbuk National University, Jeonju, Republic of Korea)

Poster 113  ‘Salmonella Gallinarum vaccine candidate with an adjuvant protein that induced immunogenicity and protective efficacy against fowl typhoid’
John Hwa Lee (Chonbuk National University, Jeonju, Republic of Korea)

Poster 114  ‘Silica particles: A versatile delivery platform for vaccine antigens’
A.Khatri et al. (Ceraminphere Pty Ltd. Gladessville, Sydney, Australia)

Poster 115  ‘Development of innovative surfactants (amphipols) carrying adjuvants for vaccination applications’
Manuela Zoonens et al. (Institut de Biologie Physico-chimique, Paris, France)

Poster 116  ‘Production of nanoemulsion adjuvants using high shear fluid processing’
Steven Mesite and Yang Su (Microfluidics International Corporation, Westwood, Massachusetts, USA)

Poster 117  ‘Freeze-dried intranasal nicotine vaccine’
Hoang Thanh Le et al. (AMRIC, Canada)

Poster 118  ‘A candidate therapeutic vaccine for uMan Chagas disease: Comparison of immune responses triggered by different delivery platforms’
J. Pollet et al. (Baylor College of Medicine Houston, Texas, USA)

Poster 119  ‘Bioluminescence from a co-delivered reporter can serve for in vivo monitoring of the specific T cell responses in gene immunization’
Stefan Petkov et al. (Karolinska Institutet, Stockholm, Sweden)

Poster 120  ‘Surrogate challenge model to assess the efficacy of HIV DNA immunogens in rodents by visualization of expression of co-delivered reporter genes’
Athea Kilpeläinen et al. (Karolinska Institutet, Stockholm, Sweden)

Poster 121  ‘Comparison of the performance of plate, plate/fork, two- and multi-needle electrodes in gene electroporation of mice’
Anastasia Latanova et al. (Karolinska Institutet, Stockholm, Sweden)

Poster 122  ‘Hepatic targeting of vaccinal antigens’
Vasiliki Panagiotou et al. (EPFL, Lausanne, Switzerland)

Poster 123  ‘Seroprevalence of measles, mumps, rubella, varicella–zoster and hepatitis A–C in Emirati medical students’
Mohamud Sheek-Hussein et al. (UAE University, Al Ain, UAE)

Poster 124  ‘Branched multi-epitope conjugates as molecular platform for subunit vaccine candidates against tuberculosis’
Kata Horvati et al. (MTA-ELTE, Budapest, Hungary)

Poster 125  ‘The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation’
Gaelle Vandermeulen et al. (Université Catholique de Louvain, Brussels, Belgium)

Poster 126  ‘Lung cancer vaccines based on liposomes containing polyi:C, a TLR-3 agonist and tumour antigens’
Christina Loira-Pastiriza et al. (Université Catholique de Louvain, Brussels, Belgium)

Poster 127  ‘Photochemical internalization – an innovative technology giving strong enhancement of Cytotoxic T-cell responses to vaccination’
Paul Kristian Selbo et al. (PCI Biotech AS, Oslo, Norway)

Poster 128  ‘OIMac analytical columns for in-process control of adenoviruses’
Tobias Baechle (BIA Separations, Ajdovscina, Slovenia)

Poster 129  ‘Monolithic columns for the downstream processing of gene therapy vectors and vaccines’
Tobias Baechle (BIA Separations, Ajdovscina, Slovenia)

Poster 130  ‘Lipovaxin, a novel adjuvant platform for recombinant protein vaccines’
Ines I. C. Atmosukarto et al. (Lipotek Pty Ltd, Australia)

Poster 131  ‘Adjuplex™ – a novel carbomer-based adjuvant platform’
Ines I. C. Atmosukarto et al. (Lipotek Pty Ltd, Australia)

Poster 132  ‘Adenoviral dodecahedron, a proteinaceous, multivalent delivery and vaccination nanoplatform with adjuvant properties’
Ewa Szolajska et al. (Polish Academy of Sciences, Warsaw, Poland)

Poster 133  ‘Layer-by-layer assembly of inactivated poliovirus and N-trimethyl chitosan on pH-sensitive microneedles for dermal vaccination’
Koen van der Maaden et al. (Leiden Academic Centre for Drug Research, Leiden, The Netherlands)

Poster 134  ‘Cell-penetrating peptide mediated DNA delivery via dissolving microneedles: An innovative platform for DNA vaccination’
J. McCaffrey et al. (Queen’s University Belfast, Belfast, Northern Ireland, UK)

Poster 135  ‘Vaccine delivery technology at Intravacc’
Ivo Ploemen et al. (Intravacc, Bilthoven, The Netherlands)

Poster 136  ‘Development of a novel, dissolvable microneedle system encapsulating peptide/DNA nanoparticles for prostate cancer vaccination’
Grace Cole et al. (Queens University Belfast, Belfast, Antrim, Northern Ireland, UK)

Poster 137  ‘The Th17 response is differentially enhanced by c-di-AMP and cGAMP’
Ivana Skrniugj et al. (Heinrich Heine University of Duesseldorf, Germany)

Poster 138  ‘Norovirus-VLPs used for delivery of pre-erythrocytic targets induce functional immunity against sporozoite infection’
Evelina Angov et al. (Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

Poster 139  ‘Preclinical comparison of a particulate and soluble CSP based vaccine against malaria’
Sheetij Dutta et al. (Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

Poster 140  ‘Versatile i-particles from Adjuvatis, for safer and efficient, fully metabolizable vaccines’
Charlotte Primard et al. (ADJUVATIS, Lyon, France)

Poster 141  ‘Neutralizing antibody responses induced by intranasal vaccination with an inactivated whole virion of influenza A(H5N1) virus in healthy human adults’
Akira Aina et al. (National Institute of Infectious Diseases, Tokyo, Japan)

Poster 142  ‘Hepatitis B virus core particles as a platform for vaccine development’
Arnis Strods et al. (Latvian Biomedical Research and Study Centre, Riga, Latvia)

Poster 143  ‘Safety and efficacy of a live Salmonella Gallinarum vaccine candidate JOL1355 compared with a commercial vaccine SG9R in chickens’
John Hwa Lee (Chonbuk National University, Jeonju, Republic of Korea)

Poster 144  ‘Salmonella Gallinarum vaccine candidate with an adjuvant protein that induced immunogenicity and protective efficacy against fowl typhoid’
John Hwa Lee (Chonbuk National University, Jeonju, Republic of Korea)

Poster 145  ‘Silica particles: A versatile delivery platform for vaccine antigens’
A.Khatri et al. (Ceraminphere Pty Ltd. Gladessville, Sydney, Australia)

Poster 146  ‘Development of innovative surfactants (amphipols) carrying adjuvants for vaccination applications’
Manuela Zoonens et al. (Institut de Biologie Physico-chimique, Paris, France)